The incidence of thyroid cancer (TC) is increasing. Although the majority of these cancers have a good prognosis, 10% of these will develop local recurrence and/or distant metastases. Conventional cytotoxic chemotherapy has been largely replaced by molecular-target therapies, but it can still have a role. Two tyrosine kinase inhibitors have been approved for the treatment of advanced differentiated TC. They significantly improve progression-free survival, but at the cost of frequent and potentially serious adverse effects. At the moment, there are multiple clinical trials with other tyrosine kinase inhibitors and other drugs. We present a review of the current standard of care and what is up to come in the treatment of advanced TC.
lesions) can be treated with local therapies such as radiotherapy or, more recently, radiofrequency ablation therapy in focal metastatic lesions [11] .
The objective of this article is to focus in the recent therapies against aggressive, advanced DTC.
Methods
A medical literature search was conducted between April and June 2017. Resources included MEDLINE via PubMed, EMBASE, Clinical Trials Databases, Cochrane Library and selected references cited in other articles. We used the controlled language of each database. The search query was (Novel OR Recent OR Advances OR New) AND (therapy OR treatment) AND aggressive AND (thyroid carcinomas OR thyroid neoplasms). The combination of these keywords was used to search the electronic databases. The included studies must have recent advances in pharmacological therapies for advanced TC, been published in the last 7 years and be written in English. Relevant studies mentioned in articles included in our search were also considered (even if older than 7 years only because of their relevance in a purpose of giving a context).
We excluded studies published more than 7 years ago, those published in a language other than English, case reports and articles focusing exclusively PDTC, ATC or MTC.
After performing the initial literature searches, each study title and abstract was screened for eligibility. Full text of all potentially relevant studies was subsequently retrieved and further examined for eligibility. 59 articles were included in this review.
Conventional cytotoxic chemotherapy
For multiple and progressive metastatic lesions with a high-tumor burden, some cytotoxic therapies have been applied [14] . Historically, adriamycin alone or in combination has been the most-common cytotoxic drug used. A retrospective study from 2008 with adriamycin alone showed only a modest efficacy with one patient achieving a partial response out of 22 patients [15] . Another retrospective study from 2013 with adriamycin plus cisplatin or cyclophosphamide showed a response rate of 20% [16] .
Other studies with nonadriamycin-based regimens have shown more consistent benefit. One from 2002 using carboplatin plus epirubicin showed a response rate of 43% in 14 RAIRTC patients [17] and another from 2012 with the gemcitabine plus oxaliplatin regimen showed an overall response of 57%. Most patients had pulmonary and lymph node metastases [14, 18] . These cytotoxic protocols can be useful and need further investigation. A Phase II study evaluating the efficacy and safety of gemcitabine plus oxaliplatin in advanced refractory TC is now enrolling patients [19] .
Molecular-target therapy

Rationale of molecular-target therapy
In recent years, advances in the genomic knowledge of DTC have opened new therapeutic opportunities.
The MAPK pathway plays a central role in PTC, which is stimulated by activating, and mutually exclusive, mutations in BRAF (around 60%), RAS family genes (13%) and RET-PTC fusion oncoproteins [20, 21] . MAPK activation also promotes expression of other oncoproteins, important for tumor microenvironment [21] . In FTC, RAS and PPARγ rearrangements are the most-common mutations [21] .
Another major signaling pathway is PI3K-AKT-mTOR, which is an important regulator of apoptosis, proliferation and cell migration. Activation of this pathway occurs in FTC, PDTC and ATC and can be the result of gain-of-function mutations in PI3K catalytic, alpha polypeptide (PI3KCA) and AKT1 or inactivating mutations in PTEN. Additionally, RAS mutations can also stimulate the PI3K-AKT-mTOR pathway, contributing to disease progression in PDTC and ATC, in which cumulative mutations are more frequent [21, 22] .
Other mutations observed in PDTC and ATC occur in TP53, ALK, EGFR, TERT and EIF1AX-RAS, the last frequently associated with RAS mutations (Figure 1 ) [22] .
Angiogenesis plays a critical role in the proliferation of DTC since peritumoral angiogenesis and microvascular density are increased in aggressive tumors. Higher VEGF and VEGFR, PDGF, and FGF and FGFR tissue levels have also been associated with aggressive behavior [21, [23] [24] [25] .
The expanding knowledge of molecular targets, described in detail in Figure 1 , may be clinically relevant. Efficacy of tyrosine kinase inhibitors in TC Tyrosine kinase inhibitors (TKIs) are increasingly being used in advanced and RAIRTC, for which the therapeutic options have been limited for decades. Two TKIs are currently approved for advanced TC, others being used off-label based on the results of Phase II trials [27, 29] and some are being studied in Phase I, II or III [27, [33] [34] .
A large systematic review and meta-analysis involving 22 studies and 1435 patients (mostly Phase II trials evaluating response in DTC but also in MTC patients), comprehending ten different TKIs, showed an objective response in 16% of DTC patients. Clinical benefit was observed in 51% of patients. Gefitinib and imatinib induced no objective responses, and pazopanib showed the highest objective response rate in DTC patients (49%). Sorafenib was the most studied TKI showing a clinical benefit in 53% of DTC patients. Lenvatinib studies were not available in this meta-analysis [35] .
The DECISION trial was a multicentric, randomized, double-blind, placebo-controlled, Phase III study that investigated sorafenib in patients with locally advanced/metastatic RAIRTC showing recent progression. A total of 417 patients were randomized to sorafenib or placebo (1:1) . Approximately 10% of patients had PDTC and 96% of patients had distant metastases. Less than 5% of patients had previously received systemic anticancer therapy [36] .
Sorafenib significantly improved progression-free survival (PFS) compared with placebo (median: 10.8 vs 5.8 months, respectively). There was no significant difference in overall survival (OS). Response rates (all partial responses) significantly increased in the sorafenib group compared with placebo (12.2 vs 0.5%). Treatment benefit occurred mostly in patients with lung metastases. Bone metastases showed only modest responses. Biochemical responses were also observed in the sorafenib arm, with initial decreases in serum thyroglobulin levels in most patients. The SELECT trial was also a Phase III, double-blind study involving patients with progressive RAIRTC, that randomly assigned 261 patients to receive lenvatinib and 131 patients to placebo. Both groups included patients with PDTC, representing more than 10% of the cases. Bone or lung metastases were present in nearly 40 and 90%, respectively, and almost 25% of patients had previously received therapy with TKI [37] .
The median PFS was significantly increased in the treatment group: 18.3 months in the lenvatinib group versus 3.6 months with placebo. The response rate was significantly greater in the lenvatinib group (64.8%, including four complete responses) against 1.5% with placebo. Progressive disease occurred in 6.9% of the patients in the lenvatinib group as compared with 39.7% in the placebo group. The difference in OS between groups was not significant.
A subanalysis of the SELECT trial showed a significant benefit in OS in older patients, but this group also had an increased frequency of severe adverse events (AEs) [38] .
A PFS benefit associated with lenvatinib and sorafenib was observed in all prespecified subgroups, and within any biomarker/genetic subgroups [36, 37] .
The benefit of TKI in OS is yet to be proven, will require more extensive trials and may be difficult to prove in crossover-designed trials.
AEs & toxicities
In the DECISION trial, AEs and dose reductions/interruptions due to treatment-related AEs were extremely frequent. The most-common AEs with sorafenib were hand-foot skin reaction, diarrhea, alopecia, rash/desquamation, fatigue, weight loss and hypertension [36] .
In the SELECT trial, AEs of any grade occurred in more than 40% of patients in the lenvatinib group, causing drug discontinuation in 14.2 and 2.3% of patients in the active treatment and placebo groups, respectively. Six of the 20 deaths that occurred during the treatment period were considered to be drug related. The main AEs with lenvatinib were hypertension, proteinuria, arterial and venous thromboembolic events, renal and hepatic failure, gastrointestinal fistula, QT prolongation and posterior reversible encephalopathy syndrome [37] .
In the meta-analysis of Klein Hesselink et al. [35] , AEs and dose reductions or discontinuations due to treatmentrelated AEs were also very common. Sorafenib and cabozantinib were associated with the highest percentage of dose reductions or discontinuation (70 and 77%, respectively) due to AEs. The most frequent AEs were hand-foot skin reaction, diarrhea and nausea/vomiting, which could be quite disabling [35] . TKIs can induce multiple AEs that require close monitoring and frequently dosage reductions or therapy suspension, depending on severity. Patients should be instructed about potential AEs and protective measures that can prevent or minimize their severity. The assessment of AEs should comprehend severity scales like the common terminology criteria for AEs since this may help to assist in treatment reductions/withdrawals [39] . Table 2 describes the most common AEs and strategies to manage them [11, [40] [41] [42] [43] [44] [45] .
Timing to stop or switch TKI Development of severe/intolerable AEs is an obvious reason to stop TKI. Progressive disease under TKI therapy (using the response evaluation criteria in solid tumors criteria) is another logical reason to stop this medication, but we need to bear in mind that there are only a few options for advanced DTC and that progression of disease may accelerate after stopping these agents. There is really no limit on the duration of treatment and some patients will experience years of drug exposure. Whether there is a real benefit of switching from one TKI to another is not clear, nevertheless, this strategy was evaluated in the SELECT trial with favorable results of lenvatinib as a second-line TKI [37] . A retrospective study also analyzed the use of a second-line TKI in advanced TC after first-line TKI failure. TC patients treated with second-line therapy in this study had a stable disease as best response. There were no significant differences in median PFS comparing first-and second-line TKI treatment [45] .
Conclusion
We are living in an era of rapid expansion in available therapies for advanced TC. TKIs can provide significant increases in PFS but carry the risk of significant toxicity. Emerging classes in experimental stages will potentially optimize the treatment of TC patients. Redifferentiation of tumors holds great promise for the future. Molecular-target therapy following a more individualized approach is a matter of special interest. Important steps to achieve efficient, well-tolerated drugs are underway, but significant work still needs to be done.
Future perspective
There are 48 Phase II-IV clinical trials enrolled at clinicaltrials.gov and 22 Phase II-IV at EU Clinical Trials Register. Details about the name of the drugs, phase of the study, primary outcomes, patients enrolled, time of start and estimated time of completion may be seen in Tables 3 & 4 [27, [46] [47] .
BRAF inhibitors
Vemurafenib and dabrafenib are small inhibitors highly selective to the BRAF-V600E mutations, which are being studied in Phase II trials [27] [28] [29] [30] .
Vemurafenib was efficient in some BRAFV600E-positive advanced RAIRTC patients (partial responses of 35-38.5% in naive patients and 26-29% in those previously exposed to a VEGFR inhibitor) [29] [30] [48] [49] . Severe AEs were noted in 65 and 68% of the two groups, respectively, [29, 48] with 22% developing cutaneous squamous cell carcinoma [28, 30] .
Dabrafenib revealed positive results in studies with BRAFV600E-mutated PTC patients, achieving new RAI uptake and partial and prolonged responses. Dabrafenib was well tolerated, with no patient requiring dose reduction even in long-term treatment [28] [29] [50] [51] .
Combination therapy of dabrafenib with lapatinib showed favorable results in patients refractory to other treatments. Dabrafenib associated with trametinib revealed promising results in recurrent TC [27, 28] . The most common AEs with these drugs are dermatological, gastrointestinal and constitutional [28, 30] .
MEK inhibitors
Selumetinib proved to be capable of reintroducing RAI uptake into RAIRTC [29, 52] . Despite a disappointing antitumor effect in one study, it was responsible for increasing RAI uptake in 60% of the cases in a mixed group of PTC and PDTC [29] . There seems to be a tumor genotype correlation with changes in RAI avidity, being the NRAS-mutant tumors those which benefit the most [29, [53] [54] . At the present time, monotherapy with selumetinib has achieved only modest success [28, 51] .
Trametinib is under evaluation in a Phase II study to test tumoral iodine reincorporation in advanced TC [27] .
mTOR inhibitors mTOR upregulation has been associated with TC [55] . Two mTOR inhibitors are being studied, everolimus and temsirolimus. The clinical results with everolimus monotherapy were disappointing, probably due to an early adaptive resistance. This could be related to a feedback loop between mTOR pathway and RAS/MAPK/ERK signaling, resulting in activation of an alternative prosurvival pathway upon mTOR inhibition. Therefore, the use of everolimus in combined therapies is now being studied [28] [29] 49, 55] . The association of sorafenib plus everolimus was already evaluated in a Phase II trial of patients who progressed on sorafenib, showing promising results. This combination is already being used as second-line therapy in centers where lenvatinib is not available [28, 49] .
ALK inhibitors ALK gene fusions, involving mainly the striatin gene (SRTN), result in increased MAPK activity and have been reported in patients with RAIRTC, specially PDTC and ATC. Crizotinib, a specific inhibitor of ALK translocation, showed promising results in ALK-mutated TC cell cultures and a clinical trial is currently underway [56, 57] .
Immunotherapy
Immunotherapy has emerged as a promising therapy since it already proved to be effective in other aggressive tumors. There is evidence of some immunological differences in advanced TC compared with normal thyroidal tissue/nonaggressive TC, such as an overexpression of mast cells, reduced peripheral natural killer cell cytotoxicity, preference by M2 phenotype in tumor-associated macrophages, inefficient dendritic cell maturation, higher concentration of myeloid-derived suppressor cells, T-cell dysfunction and overexpression of regulatory T cells [58, 59] . All of this may lead to an immune evasion by cancer cells and progression of the disease [58, 59] . There are preclinical and clinical trials at the moment studying therapies targeting tumor-associated macrophages, tumor antigens, T cells, natural killer cells and immune checkpoints [58] [59] [60] . Also, combination therapy of TKIs with other drugs such as immune checkpoint inhibitors is a matter of special interest [61] .
Immune checkpoint inhibitors at the moment have the biggest role in this class since they are the novelty responsible for improving outcomes seen in other tumors such as melanoma [62] . A study of pembrolizumab in advanced solid tumors included 22 patients with advanced DTC who failed standard treatment and showed an expression of PD-L1 ≥1% or stroma cell lines by immunohistochemistry. Preliminary results showed a 54.5% rate of stable disease, 9% rate of partial response, a 6-month OS rate of 100% and a 58.7% rate of 6-month PFS. Despite 18 patients had treatment-related AE, none of the patients needed to discontinue the drug [62] . At clinicaltrials.gov and EU Clinical Trials Register there are several studies ongoing with these drugs, such as ipilimumab plus nivolumab (two Phase II studies), pembrolizumab plus lenvatinib (one Phase II study), pembrolizumab alone (three Phase II studies), nivolumab alone (one Phase II study) and avelumab plus checkpoint agonist(s) with or without irradiation or irradiation plus cisplatin (one Phase I/II study). So, in the next few years, we will probably be able to have evidence of the efficacy of these drugs in RAIRTC [46, 47] .
Microtubule inhibitors CA4 is a naturally occurring inhibitor of tubulin that acts as an antimitotic agent, causing vascular shutdown and cell death. CA4 has already shown cytotoxic and antiproliferative activity in a variety of cancers. Recently, in a preclinical study using human thyroid papillary carcinoma cell line TPC1, CA4 showed the capacity to inhibit proliferation, migration and invasion and of promoting apoptosis. Due to these results, CA4 is considered a potential therapeutic target for the treatment of TC [63] .
Other investigational therapies
New multi-TKIs (pyrazolopyrimidines and derivatives of CLM3) and other therapeutic classes such as inhibitors of aurora kinases, proteasome, kinesin spindle protein, cancer stem cells and histone deacetylases, flavonoids, gene and apoptotic cell death-based therapies have already shown promising results in preclinical studies, and may have a role in advanced TC therapy in the future [26] [27] [58] [59] [60] [64] [65] [66] [67] [68] [69] [70] [71] . No writing assistance was utilized in the production of this manuscript.
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• The majority of differentiated thyroid cancers have a good prognosis. A minority, however, will become refractory to radioiodine and progress with local recurrence and/or distant metastases.
• Conventional cytotoxic chemotherapy has been largely replaced by molecularly targeted therapies, but it can still be useful in some patients.
• Two tyrosine kinase inhibitors have been approved for the treatment of advanced differentiated thyroid cancer (sorafenib and lenvatinib). They significantly improve progression-free survival, but at the cost of frequent and potentially serious adverse effects and without clear benefit in overall survival.
• Other multitarget tyrosine kinase inhibitors are under investigation at the moment, some with good results in preclinical trials.
• Dabrafenib and selumetinib showed promising results in the redifferentiation of thyroid tumors.
• Association of sorafenib plus everolimus showed favorable results. The association of everolimus with other drugs (i.e., lenvatinib) is being studied.
• Other drug classes such as immune checkpoint inhibitors may also have therapeutic potential.
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